Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esaxerenone in cancer survivors with hypertension and Stage B heart failure
jRCTs031260624Recruiting
- Sponsor
- Yokohama City University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of esaxerenone in hypertension (HTN) and heart failure (HF), sponsored by Yokohama City University. Primary endpoint: Percentage change from baseline in serum NT-proBNP. Started Oct 2026; status: recruiting.
02
Drugs
esaxerenone
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on jRCTs031260624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260624.